MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 464971 | Name: LG100754
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LG 100754 is a ligand of retinoid X receptor (RXR) that modulates the activity of RXR dimers. It acts as an antagonist towards RXR homodimers but as an agonist of heterodimers consisting of RXR and retinoic acid receptor (RAR) or PPARs. LG 100754, at 1 µM, is a weak agonist of RXR-PPARγ but strongly enhances signaling through the heterodimer in response to PPARγ ligands, including rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2. Through this action, LG 100754 decreases glucose levels and relieves insulin resistance in mice.

Chemical Structure

LG100754
LG100754
CAS#180713-37-5

Theoretical Analysis

MedKoo Cat#: 464971

Name: LG100754

CAS#: 180713-37-5

Chemical Formula: C26H36O3

Exact Mass: 396.2664

Molecular Weight: 396.57

Elemental Analysis: C, 78.75; H, 9.15; O, 12.10

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 615.00 2 Weeks
25mg USD 1,050.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
LG100754; LG 100754; LG-100754; CD3159; CD 3159; CD-3159; UVI 2112; UVI-2112; UVI2112;
IUPAC/Chemical Name
(2E,4E,6E)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydronaphthalen-2-yl)octa-2,4,6-trienoic acid
InChi Key
HNODNXQAYXJFMQ-ZHUZXUJZSA-N
InChi Code
InChI=1S/C26H36O3/c1-8-14-29-23-17-22-21(25(4,5)12-13-26(22,6)7)16-20(23)19(3)11-9-10-18(2)15-24(27)28/h9-11,15-17H,8,12-14H2,1-7H3,(H,27,28)/b10-9+,18-15+,19-11+
SMILES Code
CC(CCC1(C)C)(C)C2=C1C=C(/C(C)=C/C=C/C(C)=C/C(O)=O)C(OCCC)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
LG100754 (UVI 2112) is a RXR dimers modulater.
In vitro activity:
LG754 significantly increased the amount of 125I-labeled PPARγ ligand in the complex (Fig. 3D) without affecting the total amount of complex formed (Fig. 2 and data not shown). These data suggest that LG754 enhances the affinity of PPARγ for its ligands. The ability of LG100754 to both increase PPARgamma sensitivity and relieve insulin resistance implies that a deficiency in endogenous PPARgamma ligands may represent an early step in the development of insulin resistance. Reference: J Biol Chem. 2002 Apr 12;277(15):12503-6. https://pubmed.ncbi.nlm.nih.gov/11877384/
In vivo activity:
Also, LG100754 treatment of db/db mice leads to an improvement in insulin resistance in vivo. Interestingly, activation of RXR:PPARgamma by LG100268 and LG100754 occurs through different mechanisms. Reference: Mol Endocrinol. 2001 Aug;15(8):1360-9. https://pubmed.ncbi.nlm.nih.gov/11463859/
Solvent mg/mL mM comments
Solubility
DMF 30.0 75.65
DMF:PBS (pH 7.2)(1:3) 0.3 0.63
DMSO 20.0 50.43
Ethanol 5.0 12.61
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 396.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Tsuji M. Antagonist-perturbation mechanism for activation function-2 fixed motifs: active conformation and docking mode of retinoid X receptor antagonists. J Comput Aided Mol Des. 2017 Jun;31(6):577-585. doi: 10.1007/s10822-017-0025-6. Epub 2017 May 22. PMID: 28534193. 2. Forman BM. The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem. 2002 Apr 12;277(15):12503-6. doi: 10.1074/jbc.C200004200. Epub 2002 Feb 27. PMID: 11877384. 3. Cesario RM, Klausing K, Razzaghi H, Crombie D, Rungta D, Heyman RA, Lala DS. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15(8):1360-9. doi: 10.1210/mend.15.8.0677. PMID: 11463859.
In vitro protocol:
1. Tsuji M. Antagonist-perturbation mechanism for activation function-2 fixed motifs: active conformation and docking mode of retinoid X receptor antagonists. J Comput Aided Mol Des. 2017 Jun;31(6):577-585. doi: 10.1007/s10822-017-0025-6. Epub 2017 May 22. PMID: 28534193. 2. Forman BM. The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem. 2002 Apr 12;277(15):12503-6. doi: 10.1074/jbc.C200004200. Epub 2002 Feb 27. PMID: 11877384.
In vivo protocol:
1. Cesario RM, Klausing K, Razzaghi H, Crombie D, Rungta D, Heyman RA, Lala DS. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15(8):1360-9. doi: 10.1210/mend.15.8.0677. PMID: 11463859.
1: le Maire A, Teyssier C, Balaguer P, Bourguet W, Germain P. Regulation of RXR- RAR Heterodimers by RXR- and RAR-Specific Ligands and Their Combinations. Cells. 2019 Nov 5;8(11):1392. doi: 10.3390/cells8111392. PMID: 31694317; PMCID: PMC6912802. 2: Tsuji M. Antagonist-perturbation mechanism for activation function-2 fixed motifs: active conformation and docking mode of retinoid X receptor antagonists. J Comput Aided Mol Des. 2017 Jun;31(6):577-585. doi: 10.1007/s10822-017-0025-6. Epub 2017 May 22. PMID: 28534193. 3: Ayala-Peña VB, Pilotti F, Volonté Y, Rotstein NP, Politi LE, German OL. Protective effects of retinoid x receptors on retina pigment epithelium cells. Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1134-45. doi: 10.1016/j.bbamcr.2016.02.010. Epub 2016 Feb 13. PMID: 26883505. 4: Sato Y, Ramalanjaona N, Huet T, Potier N, Osz J, Antony P, Peluso-Iltis C, Poussin-Courmontagne P, Ennifar E, Mély Y, Dejaegere A, Moras D, Rochel N. The "Phantom Effect" of the Rexinoid LG100754: structural and functional insights. PLoS One. 2010 Nov 30;5(11):e15119. doi: 10.1371/journal.pone.0015119. PMID: 21152046; PMCID: PMC2994906. 5: Folkertsma S, van Noort PI, de Heer A, Carati P, Brandt R, Visser A, Vriend G, de Vlieg J. The use of in vitro peptide binding profiles and in silico ligand-receptor interaction profiles to describe ligand-induced conformations of the retinoid X receptor alpha ligand-binding domain. Mol Endocrinol. 2007 Jan;21(1):30-48. doi: 10.1210/me.2006-0072. Epub 2006 Oct 12. PMID: 17038419. 6: Hewson QC, Lovat PE, Pearson AD, Redfern CP. Retinoid signalling and gene expression in neuroblastoma cells: RXR agonist and antagonist effects on CRABP- II and RARbeta expression. J Cell Biochem. 2002;87(3):284-91. doi: 10.1002/jcb.10310. PMID: 12397610. 7: Forman BM. The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem. 2002 Apr 12;277(15):12503-6. doi: 10.1074/jbc.C200004200. Epub 2002 Feb 27. PMID: 11877384. 8: Cesario RM, Klausing K, Razzaghi H, Crombie D, Rungta D, Heyman RA, Lala DS. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15(8):1360-9. doi: 10.1210/mend.15.8.0677. PMID: 11463859. 9: Hida T, Tai K, Tokuhara N, Ishibashi A, Kikuchi K, Hibi S, Yoshimura H, Nagai M, Yamauchi T, Kobayashi S. Existence of retinoic acid-receptor-independent retinoid X-receptor-dependent pathway in myeloid cell function. Jpn J Pharmacol. 2001 Jan;85(1):60-9. doi: 10.1254/jjp.85.60. PMID: 11243576. 10: Lenhard JM, Croom DK, Weiel JE, Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2625-9. doi: 10.1161/01.atv.20.12.2625. PMID: 11116063. 11: Hamann LG. An efficient, stereospecific synthesis of the dimer-selective retinoid X receptor modulator (2E,4E,6Z)-7-[5,6,7,8- tetrahydro-5,5, 8,8-tetramethyl-2-(n-propyloxy)naphthalen-3-yl]-3-methyl octa-2,4, 6-trienoic acid. J Org Chem. 2000 May 19;65(10):3233-5. doi: 10.1021/jo991936x. PMID: 10814223. 12: Ebisawa M, Umemiya H, Ohta K, Fukasawa H, Kawachi E, Christoffel G, Gronemeyer H, Tsuji M, Hashimoto Y, Shudo K, Kagechika H. Retinoid X receptor- antagonistic diazepinylbenzoic acids. Chem Pharm Bull (Tokyo). 1999 Dec;47(12):1778-86. doi: 10.1248/cpb.47.1778. PMID: 10748721. 13: Lu HC, Revelli JP, Goering L, Thaller C, Eichele G. Retinoid signaling is required for the establishment of a ZPA and for the expression of Hoxb-8, a mediator of ZPA formation. Development. 1997 May;124(9):1643-51. PMID: 9165113. 14: Schulman IG, Li C, Schwabe JW, Evans RM. The phantom ligand effect: allosteric control of transcription by the retinoid X receptor. Genes Dev. 1997 Feb 1;11(3):299-308. doi: 10.1101/gad.11.3.299. PMID: 9030683. 15: Lala DS, Mukherjee R, Schulman IG, Koch SS, Dardashti LJ, Nadzan AM, Croston GE, Evans RM, Heyman RA. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature. 1996 Oct 3;383(6599):450-3. doi: 10.1038/383450a0. PMID: 8837780.